Ocular Therapeutix Inc. (NASDAQ: OCUL) announced additional week 52 data from its SOL-1 Phase 3 trial of AXPAXLI for wet ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE